Komori
KYORIN Pharmaceutical (4569) · InitiativeFirst stated

Out-Licensing Vibegron to Jeil in South Korea

First written in FY2020-Q3. . Latest entry: FY2020-Q3.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Out-Licensing Vibegron to Jeil in South KoreaA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2020-Q3First statedAnnual report

    「We recorded upfront income and other proceeds from the license agreement for the overactive bladder treatment vibegron signed with Jeil in South Korea as revenue.」

    An out-licensing arrangement for vibegron with Jeil in South Korea was initiated, with consideration consisting of an upfront fee, sales milestones and royalties.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Out-Licensing Vibegron to Jeil in South Korea | KYORIN Pharmaceutical Co.,Ltd. (4569) | Komori